April 19 (Reuters) - Johnson & Johnson beat
quarterly earnings forecasts on strong prescription drug revenue
and a weakening dollar, and it reassured investors that it did
not expect its blockbuster Remicade arthritis drug to face U.S.
competition this year.
Read more
No comments:
Post a Comment